|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates显示文摘 | Caroline F Odile C Didier P | 1998 | Pediatrics1998，133，1： | 1 |
| 2 | Solid phase microextraction (SPME) combined with gas-chromatography and olfactometry-mass spectrometry for characterization of cheese aroma compounds显示文摘 | DAMIAN C F CAROLINE M O JOHN P | 2004 | LWT2004，37，2： | 1 |
| 3 | Filter backwash and start-up strategies for enhanced particulate removal显示文摘 | JASON F C PETER H CAROLINE S B | 1996 | Water Research1996，30，10： | 1 |
| 4 | Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice显示文摘 | Sonveaux Pierre Végran Frédérique Schroeder Thies Wergin Melanie C Verrax Julien Rabbani Zahid N De Saedeleer Christophe J Kennedy Kelly M Diepart Caroline Jordan Bénédicte F Kelley Michael J Gallez Bernard Wahl Miriam L Feron Olivier Dewhir | 2008 | Journal of Clinical Investigation2008，，12： | 1 |
| 5 | Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation显示文摘 | Vincent C Emery Caroline A Sabin Alethea V Cope Dehila Gor Aycan F Hassan-Walker Paul D Griffiths | 2000 | The Lancet2000，，9220： | 1 |
| 6 | The influence of land transport on animal welfare in extensive farm- ing systems显示文摘 | Andrew D F Ian G C Caroline L | 2009 | Journal of Veterinary Behavior: Clini- cal Applications and Research2009，4，4： | 1 |
| 7 | Determination and influence of the main parameters for the launch and recovery of an unmanned underwater vehicle from a submarine 显示文摘 | Denis Chapuis C F Etat-Major de la Marine Caroline Dehhetl T H Didier Leandri I C N CTSN/DLSM | 1996 | IEEE1996，，： | 1 |
| 8 | Meplazumab in hospitalized adults with severe COVID-19(DEFLECT):a multicenter,seamless phase 2/3,randomized,third-party double-blind clinical trial显示文摘Meplazumab,a humanized CD147 antibody,has shown favourable safety and efficacy in our previous clinical studies.In DEFLECT(NCT04586153),167 patients with severe COVID-19 were enroled and randomized to receive three dosages of meplazumab and a placebo.Meplazumab at 0.12 mg/kg,compared to the placebo group,showed clinical benefits in significantly reducing mortality by 83.6%(2.4%vs.14.6%,p=0.0150),increasing the proportion of patients alive and discharged without supplemental oxygen(82.9%vs.70.7%,p=0.0337)and increasing the proportion of patients who achieved sustained clinical improvement(41.5%vs.31.7%).The response rate in the 0.2 mg/kg group was relatively increased by 16.0%compared with the placebo group(53.7%vs.46.3%).Meplazumab also reduced the viral loads and multiple cytokine levels.Compare with the placebo group,the 0.3 mg/kg significantly increased the virus negative rate by 40.6%(p=0.0363)and reduced IL-8 level(p=0.0460);the 0.2 mg/kg increased the negative conversion rate by 36.9%,and reduced IL-4(p=0.0365)and IL-8 levels(p=0.0484).In this study,the adverse events occurred at a comparable rate across the four groups,with no unexpected safety findings observed.In conclusion,meplazumab promoted COVID-19 convalescence and reduced mortality,viral load,and cytokine levels in severe COVID-19 population with good safety profile. | Huijie Bian Liang Chen Zhao-Hui Zheng Xiu-Xuan Sun Jie-Jie Geng Ruo Chen Ke Wang Xu Yang Shi-Rui Chen Si-Yu Chen Rong-Hua Xie Kui Zhang Jin-Lin Miao Jun-Feng Jia Hao Tang Shuang-Shuang Liu Hong-Wei Shi Yong Yang Xiao-Chun Chen Vinay Malhotra Nosheen Nasir Iffat Khanum Faisal Mahmood Saeed Hamid Claudio Marcel Berdun Stadnik Kengi Itinose Caroline Cândida Carvalho de Oliveira Cesar Dusilek Lucas Rivabem Adilson Joaquim Westheimer Cavalcante Suzara Souto Lopes Wladmir Faustino Saporito Fábio JoséConcilio Fucci Jesus Abraham Simon-Campos Ling Wang Lin-Na Liu Qing-Yi Wang Ding Wei Zheng Zhang Zhi-Nan Chen Ping Zhu | 2023 | Signal Transduction and Targeted Therapy2023，8，2： | 1 |
| 9 | Divergence in 813C of dark respired C02 and bulkorganic matter occurs during the transition betweenheterotrophy and autotrophy in Phaseolus vulgaris plants显示文摘 | BATHELLIER C BADECK F W COUZI P SeBASTIEN H CAROLINE M GHASHGHAIE J | 2008 | New Phytologist2008，，177： | 1 |
| 10 | The influence of land transport on animal welfare in extensive farming systems显示文摘 | Andrew D F Ian G C Caroline L | | 0，，04： | 1 |
| 11 | Effects of acetate on the growth and fermentation performance of Escherichia coli kol 1显示文摘 | Takahashi Caroline M Takahashi Debora F Maria L C | 1999 | Applied Biochemistry and Biotechnology1999，81，： | 1 |
| 12 | Inferring topology from clustering coefficients in protein-protein interaction networks显示文摘 | Caroline C F Ralf Z | 2006 | BMC Bioinformatics2006，7，： | 1 |
| 13 | Risk perception and knowledge of COVID-19 in patients with celiac disease显示文摘BACKGROUND We recently demonstrated that the odds of contracting coronavirus disease 2019(COVID-19)in patients with celiac disease(CeD)is similar to that of the general population.However,how patients with CeD perceive their COVID-19 risk may differ from their actual risk.AIM To investigate risk perceptions of contracting COVID-19 in patients with CeD and determine the factors that may influence their perception.METHODS We distributed a survey throughout 10 countries between March and June 2020 and collected data on demographics,diet,COVID-19 testing,and risk perceptions of COVID-19 in patients with CeD.Participants were recruited through various celiac associations,clinic visits,and social media.Risk perception was assessed by asking individuals whether they believe patients with CeD are at an increased risk of contracting COVID-19 when compared to the general population.Logistic regression was used to determine the influencing factors associated with COVID-19 risk perception,such as age,sex,adherence to a gluten-free diet(GFD),and comorbidities such as cardiac conditions,respiratory conditions,and diabetes.Data was presented as adjusted odds ratios(aORs)RESULTS A total of 10737 participants with CeD completed the survey.From them,6019(56.1%)patients with CeD perceived they were at a higher risk or were unsure if they were at a higher risk of contracting COVID-19 compared to the non-CeD population.A greater proportion of patients with CeD perceived an increased risk of contracting COVID-19 when compared to infections in general due to their CeD(56.1%vs 26.7%,P<0.0001).Consequently,34.8%reported taking extra COVID-19 precautions as a result of their CeD.Members of celiac associations were less likely to perceive an increased risk of COVID-19 when compared to non-members(49.5%vs 57.4%,P<0.0001).Older age(aOR:0.99;95%CI:0.99 to 0.99,P<0.001),male sex(aOR:0.84;95%CI:0.76 to 0.93,P=0.001),and strict adherence to a GFD(aOR:0.89;95%CI:0.82 to 0.96,P=0.007)were associated with a lower perception of COVID-19 risk and the presence of comorbidities was associated with a higher perception of COVID-19 risk(aOR:1.38;95%CI:1.22 to 1.54,P<0.001).CONCLUSION Overall,high levels of risk perceptions,such as those found in patients with CeD,may increase an individual’s pandemic-related stress and contribute to negative mental health consequences.Therefore,it is encouraged that public health officials maintain consistent communication with the public and healthcare providers with the celiac community.Future studies specifically evaluating mental health in CeD could help determine the consequences of increased risk perceptions in this population. | Jamie Zhen Juan Pablo Stefanolo María de la Paz Temprano Caroline L Seiler Alberto Caminero Enrique de-Madaria Miguel Montoro Huguet Vivas Santiago Sonia Isabel Niveloni Edgardo Gustavo Smecuol Luis Uzcanga Dominguez Elena Trucco Virginia Lopez Carolina Olano Pasquale Mansueto Antonio Carroccio Peter H Green Donald Duerksen Andrew S Day Jason A Tye-Din Julio César Bai Carolina Ciacci Elena F Verdú Benjamin Lebwohl M Ines Pinto-Sanchez | 2021 | World Journal of Gastroenterology2021，27，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员